Nucana PLC NCNA
Annual
Quarterly
No annual revenue total was found in NUCANA PLC's SEC filings.
Nucana PLC (NCNA) files with the SEC under industry code 2834, Pharmaceutical Preparations.
Revenue
—
Net income
—
Operating cash flow
—
Free cash flow
—
EPS
—
Dividend per share
None
Shares outstanding
20.81B
+14551.0% vs prior year
Net cash
—
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- NCNA (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- United Kingdom
- Headquarters
- Edinburgh, United Kingdom
- SEC filer status
- Non-accelerated filer
- SEC CIK
- 1709626
- Former names
- NuCana BioMed Ltd (until Aug 4, 2017)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 6-K | Current report (foreign issuer) | Sep 30, 2026 | Sep 30, 2026 |
| 6-K | Current report (foreign issuer) | Aug 13, 2026 | Jun 30, 2026 |
| 6-K | Current report (foreign issuer) | Jun 8, 2026 | Jun 8, 2026 |
| 6-K | Current report (foreign issuer) | Jun 1, 2026 | Jun 1, 2026 |
| 6-K | Current report (foreign issuer) | May 14, 2026 | May 14, 2026 |
| 6-K | Current report (foreign issuer) | May 6, 2026 | May 6, 2026 |
All 282 Nucana PLC SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.